Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
โ Scribed by Jeffrey D. Rothstein; Guochuan Tsai; Dr Ralph W. Kuncl; Lora Clawson; David R. Cornblath; Daniel B. Drachman; Alan Pestronk; Barbara L. Stauch; Joseph T. Coyle
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 815 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
โฆ Synopsis
Recently, the excitatory amino acid neurotransmitter glutamate was implicated in the pathogenesis of a variety of chronic degenerative neurological diseases in humans and animals. This report describes abnormalities in excitatory amino acids in the central nervous system of 18 patients with amyotrophic lateral sclerosis (ALS). The concentration of the excitatory amino acids glutamate and aspartate in the cerebrospinal fluid were increased significantly ( p < 0.01) by 100 to 200% in patients with ALS. Similarly, the concentrations of the excitatory neuropeptide N-acetyl-aspartyl glutamate and its metabolite, N-acetyl-aspartate, were elevated twofold to threefold in the cerebrospinal fluid from the patients. There was no relationship between amino acid concentrations and duration of disease, clinical impairment, or patient age. In the ventral horns of the cervical region of the spinal cord, the level of N-acetyl-aspartyl glutamate and N-acetyl-aspartate was decreased by 60% ( p < 0.05) and 40% (p < 0.05), respectively, in 8 patients with ALS. Choline acetyltransferase activity was also diminished by 35% in the ventral horn consistent with motor neuron loss. We conclude that excitatory amino acid metabolism is altered in patients with ALS. Based on neurodegenerative disease models, these changes may play a role in motor neuron loss in ALS.
๐ SIMILAR VOLUMES
Glutamate levels were determined in the fasting plasma of 22 patients with early-stage primary amyotrophic lateral sclerosis (ALS) and compared to those of healthy and diseased controls. There was a significant increase (by approximately loo%, p < 0.0005) in the plasma glutamate of the ALS patients